CA2496325A1 — Phenacyl xanthine derivatives as dpp-iv inhibitor
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2004-03-04 · 22y expired
What this patent protects
The invention concerns substituted xanthines of general formula (I), wherein : R1 to R4 are such as defined in Claim 1, and tautomers, stereoisomers, mixtures, prodrugs and salts thereof. Said compounds have advantageous pharmacological properties, in particular an inhibiting eff…
USPTO Abstract
The invention concerns substituted xanthines of general formula (I), wherein : R1 to R4 are such as defined in Claim 1, and tautomers, stereoisomers, mixtures, prodrugs and salts thereof. Said compounds have advantageous pharmacological properties, in particular an inhibiting effect on the activi ty of the dipeptidyl peptidase IV (DPP-IV) enzyme.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.